Q: What is Skyrizi used for?

Skyrizi is used to treat Crohn disease , plaque psoriasis , psoriatic arthritis , and others.

Q: How does Skyrizi work?

Mechanism of Action Skyrizi is a monoclonal antibody that belongs to a class of medications known as interleukin-23 (IL-23) inhibitors. It is designed to target and block the activity of IL-23, a protein in the body that plays a key role in the inflammatory process. Targeting Inflammation In people with conditions such as plaque psoriasis, psoriatic arthritis, or Crohn's disease, the immune system produces excessive amounts of IL-23. This overproduction acts as a signal that triggers inflammation and other symptoms. Skyrizi works by binding specifically to the p19 subunit of the IL-23 protein, which prevents it from interacting with its receptors on the surface of cells. Effects on the Body By interfering with the IL-23 signaling pathway, Skyrizi helps to: Reduce skin cell growth: In plaque psoriasis, it slows down the rapid production of skin cells, which helps clear the skin of thick, red, or scaly patches. Lower inflammation: It decreases the inflammatory response that can cause joint pain and swelling in psoriatic arthritis or intestinal damage in Crohn's disease. Regulate the immune system: Because it targets a specific protein rather than the entire immune system, it provides a more focused approach to managing autoimmune symptoms.

Q: What are the active ingredients in Skyrizi?

The active ingredient in Skyrizi is risankizumab .

Q: What are the side effects of Skyrizi?

Common side effects of Skyrizi may include: upper respiratory infection fatigue injection site reactions Always consult with a healthcare professional about potential side effects.

Q: What drug class is Skyrizi?

Skyrizi belongs to the IL-23 inhibitor drug class.

Q: What is the dosage of Skyrizi and how do I take it?

Administration Methods Skyrizi is administered either as an intravenous infusion or as a subcutaneous injection under the skin. The method of delivery depends on the specific condition being treated and whether you are receiving initial doses or maintenance therapy. For certain conditions, a healthcare professional will provide the starting doses through a vein in a clinical setting. Subsequent maintenance doses are usually self-administered or given by a caregiver using a prefilled syringe, injection pen, or an on-body injector. How to Inject Preparation: Take the medication out of the refrigerator and let it reach room temperature naturally before use. Do not shake the container or attempt to heat it. Injection Sites: Common injection sites include the front of the thighs or the abdomen. Avoid injecting into the area immediately around the navel. Skin Condition: Do not inject into skin that is bruised, red, tender, or hard. Avoid areas currently affected by psoriasis plaques. Rotation: Use a different injection site for each dose to help reduce skin irritation. Missed Dose If you miss a dose of Skyrizi, use it as soon as you remember. After that, continue with your next dose at the regularly scheduled time. Do not use extra medication to make up for a missed dose. If you are unsure of when to resume your schedule, contact your healthcare provider.

Q: Is Skyrizi safe during pregnancy and breastfeeding?

Pregnancy There are no adequate and well-controlled studies of Skyrizi in pregnant women. While animal studies using monkeys did not show evidence of harm to the fetus at doses significantly higher than the human dose, these results do not always predict human response. Because Skyrizi is a monoclonal antibody, it is expected to be transported across the placenta during the third trimester. If you are pregnant or planning to become pregnant, talk to your doctor. They will help determine if the benefits of using this medication outweigh the potential risks to the unborn baby. Breastfeeding It is not known if Skyrizi is present in human breast milk or if it has any effect on a breastfed infant or milk production. Although many monoclonal antibodies are large molecules that may not be absorbed well by an infant's digestive system, the safety profile for breastfeeding has not been established. You should discuss the risks and benefits of breastfeeding while using Skyrizi with your healthcare provider to determine the best course of action for you and your child.

Q: What forms and strengths does Skyrizi come in?

Available Forms Skyrizi is administered as an injection. The specific form used depends on the medical condition and whether the dose is for starting treatment or maintenance. Subcutaneous Injection: This form is injected into the fatty tissue under the skin. It is available as a single-dose prefilled syringe or a single-dose prefilled pen. For some conditions, it is also available as a prefilled cartridge used with an on-body injector. Intravenous Infusion: For certain conditions, such as Crohn's disease, the initial doses are given through a vein in the arm by a healthcare professional in a clinical setting. Strengths Skyrizi is supplied in various strengths and concentrations tailored to specific dosing requirements. These include single-use vials for infusion, as well as syringes, pens, and cartridges for injection under the skin.

Q: What is the FDA approval status of Skyrizi?

FDA Approval and Indications Skyrizi was first approved by the U.S. Food and Drug Administration (FDA) in 2019. It is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that works as an interleukin-23 inhibitor. The FDA has approved Skyrizi for use in adults for the following indications: Plaque Psoriasis: For the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis: For the treatment of active psoriatic arthritis in adults. Crohn's Disease: For the treatment of moderately to severely active Crohn's disease in adults. Ulcerative Colitis: For the treatment of moderately to severely active ulcerative colitis in adults. Regulatory Requirements and Safety Monitoring The FDA requires specific screening before a patient begins treatment with Skyrizi. Healthcare providers must evaluate patients for tuberculosis (TB) infection prior to initiating therapy. Treatment should not be started in patients with an active TB infection. While Skyrizi does not currently have a boxed warning, the FDA-approved labeling includes warnings regarding the risk of infections. Because the medication affects the immune system, it may increase the risk of infections or reactivate latent infections. Patients are monitored for signs and symptoms of infection during and after treatment. There is no Risk Evaluation and Mitigation Strategy (REMS) program required for Skyrizi at this time.

Question 1

What is Skyrizi?

Accepted Answer

Skyrizi is a monoclonal antibody that belongs to a class of drugs known as interleukin-23 inhibitors. It works by binding to a specific protein in the body called interleukin-23, which is involved in the inflammatory process.

By blocking this protein, the medication helps to regulate the immune system and reduce the inflammation associated with certain chronic conditions. This targeted action addresses the underlying biological activity that contributes to inflammatory symptoms.

Question 2

What is Skyrizi used for?

Accepted Answer

Skyrizi is used to treat Crohn disease, plaque psoriasis, psoriatic arthritis, and others.

Question 3

How does Skyrizi work?

Accepted Answer

Mechanism of Action

Skyrizi is a monoclonal antibody that belongs to a class of medications known as interleukin-23 (IL-23) inhibitors. It is designed to target and block the activity of IL-23, a protein in the body that plays a key role in the inflammatory process.

Targeting Inflammation

In people with conditions such as plaque psoriasis, psoriatic arthritis, or Crohn's disease, the immune system produces excessive amounts of IL-23. This overproduction acts as a signal that triggers inflammation and other symptoms. Skyrizi works by binding specifically to the p19 subunit of the IL-23 protein, which prevents it from interacting with its receptors on the surface of cells.

Effects on the Body

By interfering with the IL-23 signaling pathway, Skyrizi helps to:

Reduce skin cell growth: In plaque psoriasis, it slows down the rapid production of skin cells, which helps clear the skin of thick, red, or scaly patches.
Lower inflammation: It decreases the inflammatory response that can cause joint pain and swelling in psoriatic arthritis or intestinal damage in Crohn's disease.
Regulate the immune system: Because it targets a specific protein rather than the entire immune system, it provides a more focused approach to managing autoimmune symptoms.

Question 4

What are the active ingredients in Skyrizi?

Accepted Answer

The active ingredient in Skyrizi is risankizumab.

Question 5

What are the side effects of Skyrizi?

Accepted Answer

Common side effects of Skyrizi may include:

upper respiratory infection
fatigue
injection site reactions

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Skyrizi?

Accepted Answer

Skyrizi belongs to the IL-23 inhibitor drug class.

Question 7

What is the dosage of Skyrizi and how do I take it?

Accepted Answer

Administration Methods

Skyrizi is administered either as an intravenous infusion or as a subcutaneous injection under the skin. The method of delivery depends on the specific condition being treated and whether you are receiving initial doses or maintenance therapy.

For certain conditions, a healthcare professional will provide the starting doses through a vein in a clinical setting. Subsequent maintenance doses are usually self-administered or given by a caregiver using a prefilled syringe, injection pen, or an on-body injector.

How to Inject

Preparation: Take the medication out of the refrigerator and let it reach room temperature naturally before use. Do not shake the container or attempt to heat it.
Injection Sites: Common injection sites include the front of the thighs or the abdomen. Avoid injecting into the area immediately around the navel.
Skin Condition: Do not inject into skin that is bruised, red, tender, or hard. Avoid areas currently affected by psoriasis plaques.
Rotation: Use a different injection site for each dose to help reduce skin irritation.

Missed Dose

If you miss a dose of Skyrizi, use it as soon as you remember. After that, continue with your next dose at the regularly scheduled time. Do not use extra medication to make up for a missed dose. If you are unsure of when to resume your schedule, contact your healthcare provider.

Question 8

Is Skyrizi safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate and well-controlled studies of Skyrizi in pregnant women. While animal studies using monkeys did not show evidence of harm to the fetus at doses significantly higher than the human dose, these results do not always predict human response. Because Skyrizi is a monoclonal antibody, it is expected to be transported across the placenta during the third trimester.

If you are pregnant or planning to become pregnant, talk to your doctor. They will help determine if the benefits of using this medication outweigh the potential risks to the unborn baby.

Breastfeeding

It is not known if Skyrizi is present in human breast milk or if it has any effect on a breastfed infant or milk production. Although many monoclonal antibodies are large molecules that may not be absorbed well by an infant's digestive system, the safety profile for breastfeeding has not been established.

You should discuss the risks and benefits of breastfeeding while using Skyrizi with your healthcare provider to determine the best course of action for you and your child.

Question 9

What forms and strengths does Skyrizi come in?

Accepted Answer

Available Forms

Skyrizi is administered as an injection. The specific form used depends on the medical condition and whether the dose is for starting treatment or maintenance.

Subcutaneous Injection: This form is injected into the fatty tissue under the skin. It is available as a single-dose prefilled syringe or a single-dose prefilled pen. For some conditions, it is also available as a prefilled cartridge used with an on-body injector.
Intravenous Infusion: For certain conditions, such as Crohn's disease, the initial doses are given through a vein in the arm by a healthcare professional in a clinical setting.

Strengths

Skyrizi is supplied in various strengths and concentrations tailored to specific dosing requirements. These include single-use vials for infusion, as well as syringes, pens, and cartridges for injection under the skin.

Question 10

What is the FDA approval status of Skyrizi?

Accepted Answer

FDA Approval and Indications

Skyrizi was first approved by the U.S. Food and Drug Administration (FDA) in 2019. It is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that works as an interleukin-23 inhibitor. The FDA has approved Skyrizi for use in adults for the following indications:

Plaque Psoriasis: For the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Psoriatic Arthritis: For the treatment of active psoriatic arthritis in adults.
Crohn's Disease: For the treatment of moderately to severely active Crohn's disease in adults.
Ulcerative Colitis: For the treatment of moderately to severely active ulcerative colitis in adults.

Regulatory Requirements and Safety Monitoring

The FDA requires specific screening before a patient begins treatment with Skyrizi. Healthcare providers must evaluate patients for tuberculosis (TB) infection prior to initiating therapy. Treatment should not be started in patients with an active TB infection.

While Skyrizi does not currently have a boxed warning, the FDA-approved labeling includes warnings regarding the risk of infections. Because the medication affects the immune system, it may increase the risk of infections or reactivate latent infections. Patients are monitored for signs and symptoms of infection during and after treatment.

There is no Risk Evaluation and Mitigation Strategy (REMS) program required for Skyrizi at this time.

Question 11

What should I know about Skyrizi and cost?

Accepted Answer

Factors Influencing Cost

The out-of-pocket cost for Skyrizi is not fixed and depends on several variables related to your healthcare coverage and treatment plan:

Insurance Coverage: Your specific health insurance plan, including its formulary, deductible, and copayment or coinsurance requirements, will significantly impact the final price.
Pharmacy Choice: Skyrizi is a biologic medication and is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy, which can affect the cost.
Treatment Dosage: The cost may vary based on the dosage and frequency of administration required for your specific condition, such as plaque psoriasis, psoriatic arthritis, or Crohn's disease.

To determine the exact cost, it is recommended to contact your insurance provider. You may also speak with your healthcare provider about potential financial assistance programs that may be available for eligible patients.

Skyrizi

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Skyrizi

Hospitals.net Disclosure